General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Excreted Unchanged %
Negligible
Half-Life (Normalesrd) Hours
5-7/Unchanged
Plasma Protein Binding %
>99
Volume Of Distribution L/Kg
0.4
Dose For Normal Renal Function
200 mg bid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Benet LZ. Pharmacokinetic profile of etodolac in special populations. Eur J Rheumatol Inflamm. 1994; 14: 15-8. [PMID: 7744123]